Cargando…
The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis
INTRODUCTION: Recent studies in septic patients showed that adverse effects of hydroxyethyl starches (HESs) possibly outweigh their benefits in severely impaired physiological haemostasis. It remains unclear whether this also applies to patient populations that are less vulnerable. In this meta-anal...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301454/ https://www.ncbi.nlm.nih.gov/pubmed/25475406 http://dx.doi.org/10.1186/s13054-014-0656-0 |
_version_ | 1782353642646405120 |
---|---|
author | Jacob, Matthias Fellahi, Jean-Luc Chappell, Daniel Kurz, Andrea |
author_facet | Jacob, Matthias Fellahi, Jean-Luc Chappell, Daniel Kurz, Andrea |
author_sort | Jacob, Matthias |
collection | PubMed |
description | INTRODUCTION: Recent studies in septic patients showed that adverse effects of hydroxyethyl starches (HESs) possibly outweigh their benefits in severely impaired physiological haemostasis. It remains unclear whether this also applies to patient populations that are less vulnerable. In this meta-analysis, we evaluated the impact of various HES generations on safety and efficacy endpoints in patients undergoing cardiac surgery. METHODS: We searched the PubMed, Embase and Cochrane Central Register of Controlled Trials databases for randomised controlled trials (RCTs) in the English or German language comparing the use of HES to any other colloid or crystalloid during open heart surgery. RESULTS: Blood loss and transfusion requirements were higher for older starches with mean molecular weights more than 200 kDa compared to other volume substitutes. In contrast, this effect was not observed with latest-generation tetrastarches (130/0.4), which performed even better when compared to albumin (blood loss of tetrastarch versus albumin: standardised mean difference (SMD), −0.34; 95% CI, −0.63, −0.05; P = 0.02; versus gelatin: SMD, −0.06; 95% CI, −0.20, 0.08; P = 0.39; versus crystalloids: SMD, −0.05; 95% CI, −0.20, 0.10; P = 0.54). Similar results were found for transfusion needs. Lengths of stay in the intensive care unit or hospital were significantly shorter with tetrastarches compared to gelatin (intensive care unit: SMD, −0.10; 95% CI, −0.15, −0.05; P = 0.0002) and crystalloids (hospital: SMD, −0.52; 95% CI, −0.90, −0.14; P = 0.007). CONCLUSIONS: In this meta-analysis of RCTs, we could not identify safety issues with tetrastarches compared with other colloid or crystalloid solutions in terms of blood loss, transfusion requirements or hospital length of stay in patients undergoing cardiac surgery. The safety data on coagulation with older starches raise some issues that need to be addressed in future trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-014-0656-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4301454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43014542015-01-22 The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis Jacob, Matthias Fellahi, Jean-Luc Chappell, Daniel Kurz, Andrea Crit Care Research INTRODUCTION: Recent studies in septic patients showed that adverse effects of hydroxyethyl starches (HESs) possibly outweigh their benefits in severely impaired physiological haemostasis. It remains unclear whether this also applies to patient populations that are less vulnerable. In this meta-analysis, we evaluated the impact of various HES generations on safety and efficacy endpoints in patients undergoing cardiac surgery. METHODS: We searched the PubMed, Embase and Cochrane Central Register of Controlled Trials databases for randomised controlled trials (RCTs) in the English or German language comparing the use of HES to any other colloid or crystalloid during open heart surgery. RESULTS: Blood loss and transfusion requirements were higher for older starches with mean molecular weights more than 200 kDa compared to other volume substitutes. In contrast, this effect was not observed with latest-generation tetrastarches (130/0.4), which performed even better when compared to albumin (blood loss of tetrastarch versus albumin: standardised mean difference (SMD), −0.34; 95% CI, −0.63, −0.05; P = 0.02; versus gelatin: SMD, −0.06; 95% CI, −0.20, 0.08; P = 0.39; versus crystalloids: SMD, −0.05; 95% CI, −0.20, 0.10; P = 0.54). Similar results were found for transfusion needs. Lengths of stay in the intensive care unit or hospital were significantly shorter with tetrastarches compared to gelatin (intensive care unit: SMD, −0.10; 95% CI, −0.15, −0.05; P = 0.0002) and crystalloids (hospital: SMD, −0.52; 95% CI, −0.90, −0.14; P = 0.007). CONCLUSIONS: In this meta-analysis of RCTs, we could not identify safety issues with tetrastarches compared with other colloid or crystalloid solutions in terms of blood loss, transfusion requirements or hospital length of stay in patients undergoing cardiac surgery. The safety data on coagulation with older starches raise some issues that need to be addressed in future trials. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-014-0656-0) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-04 2014 /pmc/articles/PMC4301454/ /pubmed/25475406 http://dx.doi.org/10.1186/s13054-014-0656-0 Text en © Jacob et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Jacob, Matthias Fellahi, Jean-Luc Chappell, Daniel Kurz, Andrea The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis |
title | The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis |
title_full | The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis |
title_fullStr | The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis |
title_full_unstemmed | The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis |
title_short | The impact of hydroxyethyl starches in cardiac surgery: a meta-analysis |
title_sort | impact of hydroxyethyl starches in cardiac surgery: a meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301454/ https://www.ncbi.nlm.nih.gov/pubmed/25475406 http://dx.doi.org/10.1186/s13054-014-0656-0 |
work_keys_str_mv | AT jacobmatthias theimpactofhydroxyethylstarchesincardiacsurgeryametaanalysis AT fellahijeanluc theimpactofhydroxyethylstarchesincardiacsurgeryametaanalysis AT chappelldaniel theimpactofhydroxyethylstarchesincardiacsurgeryametaanalysis AT kurzandrea theimpactofhydroxyethylstarchesincardiacsurgeryametaanalysis AT jacobmatthias impactofhydroxyethylstarchesincardiacsurgeryametaanalysis AT fellahijeanluc impactofhydroxyethylstarchesincardiacsurgeryametaanalysis AT chappelldaniel impactofhydroxyethylstarchesincardiacsurgeryametaanalysis AT kurzandrea impactofhydroxyethylstarchesincardiacsurgeryametaanalysis |